The Many Faces of PD: Should We Consider Progression in a More Nuanced Way? Historically, cancer treatments have been graded in large part by the “response rate” they produce, the reflection of the proportion of patients whose cancers demonstrate significant tumor shrinkage on imaging scans. While stable disease, which at least reflects no disease growth, is considered a reasonable, relative victory compared to evidence of the cancer growing, we consider a treatment as failing when the cancer grows. At the same time, in patients who are being monitored off of therapy, evidence… Read More
- #LCSM Chat Topic 04/11/2019: Why research matters for lung cancer
- #LCSM Chat Topic 03/07: Biomarker Magicians (or, Why We Love Pathologists)
- #LCSM Chat Topic 2019-02-07: Is it worth the drive?
- #LCSM Chat 2019/01/06–Immunotherapy: What Patients Need To Know
- #LCSM Chat 11/29: What’s a cancer model, and why should I care?
#LCAM14 ALK biomarker cancer treatment plans clinical research clinical trials Drugs EGFR epatients FDA immunotherapy LDCT lung cancer lung cancer awareness month lung cancer risk factors lung cancer screening Medicare coverage of LDCT over-treatment patient advocates PCORI Screening self-advocacy shared decision making trials World Cancer Day